{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MSI-H+Tumors&page=3", "query": { "condition": "MSI-H Tumors", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 79, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MSI-H+Tumors&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MSI-H+Tumors&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T11:02:52.413Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04774419", "title": "Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Intensity modulated radiation therapy (IMRT)", "type": "RADIATION" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Hypofractionated IMRT", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 62, "start_date": "2021-04-02", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-07T11:02:52.413Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04774419" }, { "nct_id": "NCT04187872", "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Carcinoma (NSCLC)", "Renal Cell Carcinoma (RCC)", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Cancer", "Classical Hodgkin Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma", "Urothelial Carcinoma", "Microsatellite Instability-High Cancer", "Gastric Cancer", "Esophageal Cancer", "Cervical Cancer", "Hepatocellular Carcinoma", "Merkel Cell Carcinoma", "Brain Metastases, Adult" ], "interventions": [ { "name": "LITT + Pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2020-01-10", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2023-12-27", "last_synced_at": "2026-10-07T11:02:52.413Z", "location_count": 2, "location_summary": "Gainesville, Florida • Jacksonville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04187872" }, { "nct_id": "NCT06006923", "title": "Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MSI-H Colorectal Cancer" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anwaar Saeed", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-06-26", "completion_date": "2025-11-12", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-10-07T11:02:52.413Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06006923" }, { "nct_id": "NCT07213609", "title": "A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms, Colorectal", "Neoplasms" ], "interventions": [ { "name": "GSK5460025", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2025-10-20", "completion_date": "2028-10-27", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-07T11:02:52.413Z", "location_count": 4, "location_summary": "Aurora, Colorado • Detroit, Michigan • Canton, Ohio + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Canton", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213609" }, { "nct_id": "NCT03374254", "title": "Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil [5-FU]", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2018-02-16", "completion_date": "2023-07-18", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-10-07T11:02:52.413Z", "location_count": 10, "location_summary": "Duarte, California • Aurora, Colorado • New Haven, Connecticut + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03374254" }, { "nct_id": "NCT06034860", "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Hepatocellular Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Microsatellite Instability High", "Mismatch Repair Deficiency", "Mesothelioma", "Esophageal Squamous Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Urothelial Carcinoma", "Cervical Cancer" ], "interventions": [ { "name": "MT-8421", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Templates, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-11-01", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-10-07T11:02:52.413Z", "location_count": 5, "location_summary": "Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06034860" }, { "nct_id": "NCT05200559", "title": "T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "E7777", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexander B Olawaiye, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2022-09-30", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-07T11:02:52.413Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05200559" }, { "nct_id": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "Ad-p53", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MultiVir, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-10-01", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2020-06-09", "last_synced_at": "2026-10-07T11:02:52.413Z", "location_count": 3, "location_summary": "Chicago, Illinois • Morristown, New Jersey", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03544723" }, { "nct_id": "NCT05836584", "title": "Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage I Gastric Cancer AJCC v8", "Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage II Gastric Cancer AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Lymphadenectomy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-12-06", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-07T11:02:52.413Z", "location_count": 133, "location_summary": "Dublin, California • Fremont, California • Fresno, California + 99 more", "locations": [ { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05836584" }, { "nct_id": "NCT03832569", "title": "Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Solid Tumors", "Identified by NGS, PCR or IHC" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2019-02-20", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-07T11:02:52.413Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03832569" } ] }